Search SNDX
Syndax Pharmaceuticals Inc
Nasdaq · CIK 1395937
Last close17.6
Daily change-0.62 (-3.40%)
10 Years gain+13.62%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
SNDX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
60.6Momentum
100.0Acceleration
60.0Confidence
81.0Annual Revenue11
Quarterly Revenue38
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality14.8 / 25
Capital Efficiency4.0 / 20
Balance Sheet13.8 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 816.7105 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
ROIC declining · MEDIUMROIC declined by 2402.2287 percentage points.
Key Metrics
Revenue Growth TTM514.51%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin100%OK
Operating Margin-90.74%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-2,665.51%OK
Incremental Operating Margin 3Y-53.41%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.27%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $172.35M | $172.35M | -$273.08M | -$322.98M | -$323.17M | 100% | -158.45% | -187.5% | -587.92% | 86.63M |
| 2025 FY Dec 31, 2024 | $23.68M | $23.68M | -$339.67M | -$274.90M | -$274.90M | 100% | -1,434.43% | -1,160.91% | -1,265.19% | 85.62M |
| 2025 FY Dec 31, 2023 | $0.00 | $0.00 | -$229.95M | -$160.60M | -$160.60M | n/a | n/a | n/a | n/a | 70.37M |
| 2024 FY Dec 31, 2022 | $0.00 | $0.00 | -$151.76M | -$133.68M | n/a | n/a | n/a | n/a | n/a | 60.76M |
| 2023 FY Dec 31, 2021 | $139.71M | $139.71M | $26.22M | $29.13M | $29.00M | 100% | 18.77% | 20.76% | n/a | 53.62M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $221.48M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-332750, 0001193125-25-262521 |
| Revenue Growth TTM | 514.51% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-332750, 0001193125-25-262521 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001193125-26-076536 |
| Revenue CAGR 5Y | 157.68% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-076536 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001193125-26-076536 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-332750, 0001193125-25-262521 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-332750, 0001193125-25-262521 |
| Operating Margin | -90.74% | Operating Income / Revenue | OK | 0001193125-26-332750, 0001193125-25-262521 |
| ROIC | -2,665.51% | NOPAT / Average Invested Capital | OK | 0001193125-26-332750, 0001193125-25-262521 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-332750 |
| Current Ratio | 6.77x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.59x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-332750 |
| Revenue per Diluted Share | $2.49 | Revenue / Diluted Shares | OK | 0001193125-26-332750, 0001193125-25-262521 |